Pharmaceutical industry – Page 9
-
OpinionScents and sentimentality
Deprived of familiar lab odours, Derek Lowe indulges in some nasal nostalgia
-
BusinessTrials start of mRNA vaccine for HIV
First steps towards protection from the many and variable viral strains
-
NewsExplainer: How do the Covid vaccines measure up against each other and omicron?
Looking at how the evidence stacks up for vaccines against variants and how their performance holds up over time
-
OpinionThe shadow of drug resistance
Why do some medicines stop working, and can we avoid it for Covid-19 antivirals?
-
BusinessMartin Shkreli fined and banned from pharma for life
‘Pharma Bro’ must pay back $65m in profits for anticompetitive behaviour while leading Turing Pharmaceuticals
-
OpinionThe law of conservation of data
AI and machine learning are useful and powerful, but they need high quality data inputs that aren’t available yet for drug discovery
-
BusinessUS judge overturns Purdue’s opioid bankruptcy settlement
Ruling says bankruptcy court did not have authority to grant Sackler family protection from future litigation
-
OpinionWhen regulatory cooperation goes too far, we all lose
Were FDA staff unduly influenced by Biogen in approving Alzheimer’s antibody?
-
BusinessPharmaceuticals roundup 2021
It’s been another dramatic, pandemic-dominated year for the pharmaceutical industry
-
WebinarUsing flow chemistry to give early drug discovery processes a boost
Discover how pioneering modular flow chemistry technologies can unlock the potential for discovery chemists to accelerate research
-
BusinessDiversity is at the heart of innovation
To challenge conventions we need to include people who think differently
-
BusinessPfizer sues former employee for alleged trade secret theft
Chun Xiao Li downloaded thousands of confidential documents before resigning
-
OpinionA red pill for green medicines
The pharmaceutical industry is taking action towards net zero
-
BusinessCovid-19 antivirals surge forward
Promising results from Pfizer trial, while UK approves Merck & Co’s molnupiravir
-
OpinionAll work and no play
Is the long-hours culture of academic organic chemistry laboratories finally changing?
-
ArticleFacilitating the future
A view from the top at Johnson Matthey on the future of drug development
-
BusinessPredicting and preventing production losses with AI
Seebo’s machine learning technology helps chemical manufacturers get deep insight into their processes
-
ArticleAstraZeneca explores new frontiers through academic collaborations
The important of partnerships between industry and academia to drive innovation
-
BusinessNew antiviral impresses against Covid-19
Merck & Co and Ridgeback’s molnupiravir reduces risk of hospitalisation and death, and may work against other coronaviruses
-
OpinionWhere are the Covid-19 drugs?
Small molecules appear to be lagging behind development of vaccine and antibody treatments